Results 121 to 130 of about 477,779 (215)

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Clinicopathological Features of Non-Small Cell Lung Carcinoma with NRAS Mutation. [PDF]

J Pers Med
Ambrosini-Spaltro A, Rengucci C, Capelli L, Chiadini E, Bennati C, Delmonte A, Vecchiarelli S, Limarzi F, Nosseir S, Gallo G, Valli M, Ulivi P, Calistri D.   +12 more
europepmc   +1 more source

Mechanisms of Pericyte‐Mediated Cancer Metastasis

Advanced Science, EarlyView.
Pericytes play multifarious roles in promoting cancer metastasis by facilitating metastatic cancer cell dissemination, circulating tumor cell survival, tissue extravasation, premetastatic niche formation, and metastatic tumor growth. These cells have intertwined interactions with vascular endothelial cells to modulate cancer cell behavior and ...
Ziheng Guo, Yihai Cao
wiley   +1 more source

Non-small cell lung carcinoma with co-expression of thyroid transcription factor-1 and p40: a case report and literature review. [PDF]

World J Surg Oncol
Wei C, Wang Y, Lu W, Lin BY, Gan D, Lu Y.   +5 more
europepmc   +1 more source

ROS‐Responsive Nanobubbles for Dual‐Enhanced Ultrasound and Magnetic Resonance Imaging of Tumor Oxidative Stress

Advanced Science, EarlyView.
We report the development of biotinylated PEGylated bilirubin‐coated perfluoropentane (bt‐PEG‐BR@PFP) nanobubbles, a novel class of ROS‐activatable and dual‐modality contrast agents that amplify both ultrasound (US) and magnetic resonance imaging (MRI) signals in response to elevated ROS.
Wonsik Jung, Youngju Son, Dong Yun Lee, Youngeun Jeon, Muhammad Asaddudin, Sung‐Hong Park, Sangyong Jon   +6 more
wiley   +1 more source

Rare Combined Small-Cell Lung Carcinoma With Lymph Node Metastasis Exclusive to the Small-Cell Component: A Case Report. [PDF]

Cureus
Bendadi S, El Karnighi O, El Ouazzani M, Rais H, Belbaraka R.   +4 more
europepmc   +1 more source

Large‐Scale Quantitative Morphometry of Platelet α‐Granules via SIM Super‐Resolution Microscopy for Cancer Liquid Biopsy

Advanced Science, EarlyView.
ABSTRACT Blood‐based liquid biopsies hold transformative potential for non‐invasive cancer management, but current approaches relying on rare circulating tumor components limit their broad clinical utility. Platelets, abundant in blood and mediating diverse cancer‐associated responses, represent a compelling yet largely unexplored alternative.
Yan Ma, Huan Deng, Zelin Liu, Simei Zhong, Liangliang Wang, Mu He, Ning Jing, Lihua Dai, Yuzhen Basang, Xiao‐Yu Hu, Changyi Zhang, Huimin Zeng, Haoren Shao, Zhe Yang, Shanshan Zhao, Xiaohai Hu, Chuanjie Zhang, Xiaowei Wu, Jing Xu, Shaoqun Zeng, Jing Yuan, Qiang Li, Ziwei Qu, Zhenya Hong, Lingjuan Chen, Hanhua Dong, Jia Guo, Zhiqiang Han, Yu‐Hui Zhang   +28 more
wiley   +1 more source

Current and future therapies for small cell lung carcinoma. [PDF]

J Hematol Oncol
Zhai X, Zhang Z, Chen Y, Wu Y, Zhen C, Liu Y, Lin Y, Chen C.   +7 more
europepmc   +1 more source

Discovery of a Potent Fluorescence Polarization Probe for Identifying USP1 Allosteric Inhibitors

Advanced Science, EarlyView.
This study presents the first ubiquitin‐specific protease 1 (USP1) allosteric fluoroprobe and fluorescence polarization assay, enabling the differentiation of allosteric and catalytic site inhibitors. Further, a novel class of tetrahydroisoquinoline‐based USP1 inhibitors is designed, with compound 14a (USP1 IC50 = 29.9 nM) showing strong selectivity ...
Jiawei Cheng, Peipei Wang, Pengfei Wang, Jiamin Wang, Baiyang Li, Daqing Fang, Jian He, Xiaobei Hu, Weijuan Kan, Yubo Zhou, Chunpu Li, Jia Li, Hong Liu   +12 more
wiley   +1 more source

Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC): A systemic review from 2020-2025. [PDF]

Saudi Med J
Kariri YA, Alqasmi MH, Alqahtani BS.
europepmc   +1 more source